BG103842A - 5,7-disubstituted 4-aminopyrido [2,3-d]pyrimidine compounds and their application as adenosinekinase inhibitors - Google Patents

5,7-disubstituted 4-aminopyrido [2,3-d]pyrimidine compounds and their application as adenosinekinase inhibitors

Info

Publication number
BG103842A
BG103842A BG103842A BG10384299A BG103842A BG 103842 A BG103842 A BG 103842A BG 103842 A BG103842 A BG 103842A BG 10384299 A BG10384299 A BG 10384299A BG 103842 A BG103842 A BG 103842A
Authority
BG
Bulgaria
Prior art keywords
alkyl
heteroaryl
aryl
compound
heterocyclic group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BG103842A
Other languages
Bulgarian (bg)
Inventor
Shripad Bhagwat
Chih-Hung Lee
Marlon Cowart
Jeffrey MKIE
Anne GRILLOT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of BG103842A publication Critical patent/BG103842A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

The method of adenosinekinase inhibition includes the application of a compound with the formula where R1 & R2, separately, are selected from H, lower alkyl, C1-C6 alkoxyC1-C6 alkyl, arylC1-C6 alkyl, -C(O)C1-C6 alkyl, -C(O)aryl, -C(O)heterocyclyl, or can be bound together with the nitrogen to which they are attached forming 5-7-member ring optionally containing 1-2 additional heteoratoms selected from O, N or S, R3 is of the group including lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclic group, heteroarylalkyl or heterocycloalkyl where the heteroaryl or the heterocyclic group are directly or indirectly bound by a ring carbon atom, R4 is from the group including lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclic group, heteroarylalkyl or heteorcycloalkyl, and the pinctured line --- means optional presence of a double bond provided that the suitable valencies are preserved. The invention also relates to a pharmaceutical composition containing therapeutically effective quantity of the compound in a combination with a pharmaceutically acceptable carrier, to a method for the treatment of cerebral ischaemia, epilepsy, pain killing, inflammation and sepsis in mammals where therapeutically effective quantity of the compound is administered, and to a method for the preparation of the above compounds and compounds with formula I. 19 claims
BG103842A 1997-04-16 1999-10-29 5,7-disubstituted 4-aminopyrido [2,3-d]pyrimidine compounds and their application as adenosinekinase inhibitors Pending BG103842A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83821697A 1997-04-16 1997-04-16
PCT/US1998/007207 WO1998046605A1 (en) 1997-04-16 1998-04-14 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BG103842A true BG103842A (en) 2000-06-30

Family

ID=25276561

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103842A Pending BG103842A (en) 1997-04-16 1999-10-29 5,7-disubstituted 4-aminopyrido [2,3-d]pyrimidine compounds and their application as adenosinekinase inhibitors

Country Status (18)

Country Link
EP (1) EP0989986A1 (en)
JP (1) JP2001520655A (en)
KR (1) KR20010006509A (en)
CN (1) CN1252070A (en)
AR (1) AR012436A1 (en)
AU (1) AU7108398A (en)
BG (1) BG103842A (en)
BR (1) BR9809055A (en)
CA (1) CA2286909A1 (en)
CO (1) CO4940446A1 (en)
HU (1) HUP0001434A3 (en)
IL (1) IL131618A0 (en)
NO (1) NO995036D0 (en)
PL (1) PL336304A1 (en)
SK (1) SK141799A3 (en)
TR (1) TR199902455T2 (en)
WO (1) WO1998046605A1 (en)
ZA (1) ZA983177B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
HU229604B1 (en) 2001-02-12 2014-02-28 Hoffmann La Roche 6-substituted pyrido-pyrimidines, process for their preparation and pharmaceutical compositions containing them
KR20040085151A (en) 2002-01-17 2004-10-07 뉴로젠 코포레이션 Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
DE10335183A1 (en) * 2003-07-30 2005-02-24 Bayer Cropscience Ag Fungicidal drug combinations
CN101243081A (en) * 2005-07-21 2008-08-13 霍夫曼-拉罗奇有限公司 Pyrido[2,3-d]pyrimidine-2,4-diamine compounds as PTP1B inhibitors
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
KR20080080395A (en) * 2005-12-21 2008-09-03 아보트 러보러터리즈 Anti-viral compounds
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
WO2009029632A1 (en) * 2007-08-27 2009-03-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
MX2010002098A (en) 2007-08-31 2010-03-30 Eisai R&D Man Co Ltd Polycyclic compound.
DE102007061764A1 (en) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellated cyanopyridines and their use
CN102333777B (en) * 2009-02-26 2014-06-25 卫材R&D管理有限公司 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
WO2014055595A1 (en) 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
KR102375929B1 (en) 2016-03-31 2022-03-16 온크터널 테라퓨틱스, 인코포레이티드. Indoline analogs and uses thereof
CN110256420B (en) * 2019-05-07 2020-04-28 江西中医药大学 Tetrahydropyridopyrimidine derivatives, their preparation and use
CN110283171A (en) * 2019-07-17 2019-09-27 鼎泰(南京)临床医学研究有限公司 Compound of the one kind containing Pyridopyrimidine -4- amine structure, pharmaceutical composition and its application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324731A (en) * 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds

Also Published As

Publication number Publication date
HUP0001434A3 (en) 2001-01-29
WO1998046605A1 (en) 1998-10-22
EP0989986A1 (en) 2000-04-05
CA2286909A1 (en) 1998-10-22
NO995036L (en) 1999-10-15
CO4940446A1 (en) 2000-07-24
CN1252070A (en) 2000-05-03
PL336304A1 (en) 2000-06-19
ZA983177B (en) 1999-01-22
NO995036D0 (en) 1999-10-15
AU7108398A (en) 1998-11-11
SK141799A3 (en) 2000-08-14
HUP0001434A2 (en) 2000-10-28
BR9809055A (en) 2000-08-08
TR199902455T2 (en) 2000-01-21
KR20010006509A (en) 2001-01-26
AR012436A1 (en) 2000-10-18
JP2001520655A (en) 2001-10-30
IL131618A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
BG103842A (en) 5,7-disubstituted 4-aminopyrido [2,3-d]pyrimidine compounds and their application as adenosinekinase inhibitors
UA66825C2 (en) Azapolycyclic compounds condensed with aryl
CA2401229A1 (en) Aryl fused azapolycyclic compounds
TW369535B (en) A pyrazolopyridine compound and the process for preparing thereof
HU907660D0 (en) Process for producing tricyclic compounds and pharmaceutical preparatives containing such compounds as active substances
MA27582A1 (en) BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
DE69613365D1 (en) ESTER OF 5-AMINOLEVULINIC ACID AS A MEANS FOR PHOTOSENSITIZATION IN CHEMOTHERAPY
IL172833A0 (en) Pyrimidine-2,4-dione derivatives and pharmaceutical compositions containing the same
IL133891A0 (en) 2-valproenoic acid amide derivatives, their preparation and pharmaceutical compositions containing them
ATE315397T1 (en) NEUROTROPHIN ANTAGONISTS FOR THE TREATMENT OF EPILEPSY, ALZHEIMER'S DISEASE AND PAIN
PL305457A1 (en) Galantamine derivatives, method of obtaining them and their application as drugs
EP0779889A4 (en) PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE
DE68926981D1 (en) Cephem compounds and processes for their preparation
AP9300561A0 (en) Antibiotic compounds.
EA200100597A2 (en) New 1,1- and 1,2-disubstituted cyclopropane compounds, a process for their preparation and pharmaceutical compositions containing them
YU69699A (en) Aryl carboxylic acid and tetrazole derivatives
ATE144423T1 (en) THERAPEUTIC BENZAZEPINE COMPOUNDS
DK0541407T3 (en) Nitrogen-containing bicyclic derivatives, processes for their preparation and pharmaceutical compositions containing them
EA199700287A1 (en) BENZAMIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
IL148196A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
PT85869A (en) Process for preparing amino acid derivative anti-convulsant
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
BG103861A (en) 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
KR970704723A (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents (DIHYDROBENZOFURAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS)
BG103853A (en) 5, 6, 7-trisubstituted 4-aminopyridol[2,3-d]pyrimidine compounds